Literature DB >> 18594400

Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach.

Amir H Dorafshar1, Sara R Dickie, Alvin B Cohn, Joyce K Aycock, Annemarie O'Connor, Avery Tung, Lawrence J Gottlieb.   

Abstract

BACKGROUND: Toxic epidermal necrolysis syndrome is a devastating disease, with mortality rates ranging between 20 and 60 percent. This study evaluated an alternative treatment approach using antishear wound care and compared outcomes using the severity of illness score for toxic epidermal necrolysis syndrome (SCORTEN) system.
METHODS: Records of 48 patients with a histopathologic diagnosis of toxic epidermal necrolysis syndrome treated with burn equivalent critical care and antishear wound care from September of 1985 to April of 2004 were reviewed. Observed mortality data were compared with those expected using the SCORTEN, and the standardized mortality ratio was calculated.
RESULTS: The overall mortality rate was 27 percent. Factors affecting mortality were advancing age, time to burn unit admission, multisystem organ failure, and presence of comorbidities (p = 0.02, p = 0.02, p < 0.001, and p = 0.003, respectively). Chronic renal insufficiency and malignancy were two independent risk factors for nonsurvival (p = 0.04 and p = 0.004, respectively). Patients with a SCORTEN score of 2 or less had no mortality rate in this series. Observed and predicted mortality rates were comparable for patients with SCORTEN scores of 3 or greater. Patients with combined scores of 3 or less had a standardized mortality ratio score of 0.58 (42 percent mortality reduction). Overall, the standardized mortality ratio was 0.89 (11 percent mortality reduction).
CONCLUSIONS: Transfer to a burn intensive care unit and initiation of critical care and wound protocols similar to those used for burn patients are recommended for patients with toxic epidermal necrolysis syndrome. Antishear wound care provides an effective alternative wound care approach with equivalent mortality rates.

Entities:  

Mesh:

Year:  2008        PMID: 18594400     DOI: 10.1097/PRS.0b013e3181773d5d

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  8 in total

Review 1.  Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Authors:  Olivia A Charlton; Victoria Harris; Kevin Phan; Erin Mewton; Chris Jackson; Alan Cooper
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-09       Impact factor: 4.730

Review 2.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

Review 3.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

Review 4.  Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.

Authors:  Stefanie Zimmermann; Peggy Sekula; Moritz Venhoff; Edith Motschall; Jochen Knaus; Martin Schumacher; Maja Mockenhaupt
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

Review 5.  Bullous Drug Reactions.

Authors:  Maja Mockenhaupt
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

6.  Stevens-Johnson Syndrome.

Authors:  Jake Laun; Katie Laun; Mayssan Muftah; Amanda Zimmerman; Joshua B Elston; David J Smith
Journal:  Eplasty       Date:  2016-12-07

Review 7.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.

Authors:  Jeremy A Schneider; Philip R Cohen
Journal:  Adv Ther       Date:  2017-04-24       Impact factor: 3.845

8.  Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins).

Authors:  Saskia Ingen-Housz-Oro; Tu-Anh Duong; Benoit Bensaid; Nathalia Bellon; Nicolas de Prost; Dévy Lu; Bénédicte Lebrun-Vignes; Julie Gueudry; Emilie Bequignon; Karim Zaghbib; Gérard Royer; Audrey Colin; Giao Do-Pham; Christine Bodemer; Nicolas Ortonne; Annick Barbaud; Laurence Fardet; Olivier Chosidow; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.